FORM
6-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of
Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the
Securities Exchange Act of 1934
|
For
the month ended
|
|
Commission
File Number
|
|
January
2006
|
|
1-32608
|
|
VIREXX
MEDICAL CORP.
|
|
(Translation
of registrant's name into English)
|
|
8223
Roper Road NW, Edmonton, Alberta, Canada T6E 6S4
|
|
(Address
of principal executive offices)
|
Indicate
by check mark whether the registrant files or will file annual reports
under
cover Form 20-F or Form 40-F.
|
Form
20-F
|
[X] |
Form
40-F
|
[ ] |
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): [
]
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes
|
[ ] |
No
|
[X] |
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ____
EXHIBIT
INDEX
Exhibit
| Number |
Description
of Exhibit
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
VIREXX
MEDICAL CORP.
|
||
| |
|
|
| Date: February 8, 2006 | By: | /s/Tracy Smith |
|
|
||
| Investors Relations Manager | ||
|
|
AMEX
“REX”
|
|
TSX
Exchange “VIR”
|
|
| ViRexx Medical Corp. |
For
Immediate Release
|
EDMONTON,
ALBERTA - January 19, 2005
- ViRexx
Medical Corp. (TSX:VIR, AMEX:REX), a company focused on immunotherapy treatments
for certain cancers, chronic hepatitis B & C and embolotherapy treatments
for tumors, today announced that its founders, Dr. Antoine Noujaim and Dr.
Lorne
Tyrrell, will receive a Lifetime Achievement Award from BioAlberta at the
6th
Annual
BioAlberta Gala taking place tonight in Edmonton at the Fairmount MacDonald
Hotel.
“Dr.
Noujaim and Dr. Tyrrell are deserving recipients of this prestigious award
for
their contribution to both science and the biotech industry in Alberta,” said
Doug Gilpin CA, Chairman of the Board of ViRexx Medical Corp. “The dedication
they have demonstrated to their work and the progress they continue to make
toward new medical therapies is recognized across the country and
internationally. We continue to draw upon their experience and knowledge in
the
development and application of our immunotherapy and embolotherapy
technologies.”
The
Lifetime Achievement Award recognizes individuals who have made extensive and
tangible contributions to the Alberta and Canadian life sciences community,
and
honor the impact of that work on scientific achievement and research, industry
development, public policy, ambassadorship, and education. Recipients are
categorized as passionate advocates for science and technology, accomplished
scientists and/or business leaders, and mentors to many within the
industry.
About
ViRexx Medical Corp.
ViRexx
is
an Edmonton, Alberta based biotechnology company focused on the development
of
novel therapeutic products for the treatment of certain cancers and specified
chronic viral infections. ViRexx’s most advanced programs include drug
candidates for the treatment of ovarian cancer, chronic hepatitis B and C and
solid tumors.
ViRexx’s
lead product candidate, OvaRex®
MAb, a
therapy for the treatment of late-stage ovarian cancer, is currently the subject
of two Phase III clinical trials being funded by ViRexx’s licensing partner
Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation.
For additional information about ViRexx, please see www.virexx.com.
About
BioAlberta
BioAlberta
is a private, not-for-profit industry association, representing BioAlberta’s
growing biotechnology sector. BioAlberta currently lists over 100 members,
including producers, users and supporters of biotechnology activities in
Alberta. On behalf of its membership, BioAlberta promotes increased awareness
and support for the growth of Alberta’s biotechnology industry and biotech
capabilities across all sectors.
THE
TSX
HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION CONTAINED HEREIN
This
news release contains certain forward-looking statements that reflect the
current views and/or expectations of the Company with respect to its
performance, business and future events. Such statements are subject to a number
of risks, uncertainties and assumptions. Actual results and events may vary
significantly.
For
more information, please contact:
|
Lorne Tyrrell
Chief Executive Officer
ViRexx Medical Corp.
Tel: (780) 433-4411
Fax: (780) 436-0068
ltyrrell@virexx.com
|
Marc Canton
President & Chief Operating Officer
ViRexx Medical Corp.
Tel: (780) 433-4411
Fax: (780) 436-0068
mcanton@virexx.com
|